Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12034868 | 0.80 | HPGD (0.40) | HPGDALDH1A1HSD17B10GAAF10 | |
| SCHEMBL1308824 | 0.79 | HSD11B1 (0.43) | HPGDALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL30138440 | 0.78 | HTT (0.62) | HCAR3FGFR1HPGDALDH1A1LMNA | |
| SCHEMBL1307232 | 0.78 | HSD11B1 (0.39) | — | |
| SCHEMBL12034878 | 0.78 | HSD11B1 (0.39) | — | |
| SCHEMBL12052701 | 0.77 | NPC1 (0.43) | HPGDALDH1A1GAAKMT2A | |
| SCHEMBL31183038 | 0.77 | HCAR3 (0.55) | HCAR3FGFR1HPGDALDH1A1LMNA | |
| SCHEMBL1308827 | 0.77 | HPGD (0.41) | HPGDALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL30138443 | 0.76 | HCAR3 (0.58) | HCAR3FGFR1HPGDALDH1A1LMNA | |
| SCHEMBL3816420 | 0.76 | HCAR3 (0.54) | HCAR3FGFR1HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | claimed |
| CN-101355938-A | Pharmaceutical use of substituted amides | TRANSTECH PHARMA INC (US) | 2009-01-28 | — | — | CN | claimed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| CN-101355938-A | Pharmaceutical use of substituted amides | TRANSTECH PHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | HCAR3 506/4885FGFR1 3010/4885HPGD 27/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | HCAR3 488/4885FGFR1 3384/4885HPGD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.